Cytokine gene-mediated immunotherapy: current status and future perspectives

Area of Science:

• Immunology
• Oncology
• Gene Therapy

Background:

• The tumor microenvironment often suppresses anti-cancer immunity.
• Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-12 (IL-12) are key cytokines for activating anti-tumor immune responses.
• Gene modification offers a strategy to enhance these immune responses.

Purpose of the Study:

• To review the antitumor mechanisms of gene-modified cells secreting GM-CSF or IL-12.
• To discuss the clinical applications of these immunotherapies in preclinical and clinical settings.
• To explore the potential of these strategies in combination with other cancer treatments.

Main Methods:

• Review of preclinical and clinical studies involving gene-modified tumor cells and dendritic cells.
• Analysis of the role of GM-CSF and IL-12 in activating dendritic cells and immune responses.
• Examination of vaccination strategies utilizing gene-modified cells.

Main Results:

• Gene-modified cells secreting GM-CSF or IL-12 demonstrate significant antitumor effects.
• These approaches effectively activate dendritic cells and boost immune responses against cancer.
• Successful preclinical and clinical applications have been documented.

Conclusions:

• Gene-modified cell-based immunotherapy secreting GM-CSF or IL-12 is a promising strategy for cancer treatment.
• These methods enhance antitumor immunity by overcoming the immunosuppressive tumor microenvironment.
• The principles of these vaccination strategies may be applicable to other immunotherapies and combination treatments.